Tarsus Pharmaceuticals
Irvine, California, United States · Biopharma, Biotechnology, Health Care
Tarsus Pharmaceuticals, Inc. is a company specializing in biological products. They have shown substantial growth and have strategic initiatives in place, including the recent appointment of Dr. Elizabeth Yeu as the new Chief Medical Officer.
Key facts
- Headquarters
- Irvine, California, United States
- Employees
- 370
- Industries
- Biopharma, Biotechnology, Health Care
- Status
- Public (TARS)
- Website
- tarsusrx.com
- Company page
Recent activity at Tarsus Pharmaceuticals
- : Tarsus Pharmaceuticals to acquire Alkeus Pharmaceuticals
- : Tarsus Pharmaceuticals secures $125.0 million in oversubscribed Private Placement Equity Financing, led by Barclays with participation from TCGX and Bain Capital. The funds will support clinical development and corporate activities.
- : Tarsus Pharmaceuticals Appoints Neera Clase as Interim Chief Commercial Officer
- : Tarsus acquires iRenix Medical for IRX-101 development
- : SEC 8-K (2.01): On September 4, 2026, Tarsus Pharmaceuticals, Inc. completed its acquisition of Alkeus Pharmaceuticals, Inc. through a merger, finalizing a transaction valued at approximately $270 million in cash and stock. Along with the initial consideration, Tarsus has committed to pay up to $350 million in milestone payments upon achieving regulatory approval for Alkeus products and an additional $100 million upon their first sale in the U.S. The acquisition was executed through a specified Agreement and Plan of Merger, marking a significant expansion of Tarsus's portfolio. This strategic move allows Tarsus to integrate Alkeus's assets and products, potentially enhancing their market position. The financial terms illustrate substantial future growth potential contingent upon product approvals and sales.
- : SEC 8-K (1.01): On August 5, 2026, Tarsus Pharmaceuticals, Inc. entered into a Securities Purchase Agreement with a syndicate of investors for a private placement of 2,098,519 shares of common stock at $56.00 per share and pre-funded warrants for an additional 133,625 shares at a price of $55.9999 each. The private placement is expected to close on August 7, 2026, with gross proceeds of approximately $125.0 million, intended to fund clinical development and general corporate purposes. The agreement includes customary conditions and a lock-up period of 90 days for directors and officers, limiting their ability to sell or pledge shares during this time. The deal reflects the company’s strategy to enhance its financial resources for ongoing operations and growth.
- : SEC 8-K (1.01):
- : SEC 8-K (5.02): On July 13, 2026, Tarsus Pharmaceuticals, Inc. announced the departure of Aziz Mottiwala from his role as Chief Commercial Officer. Mottiwala will leave the Company on July 15, 2026, to take on a new position as Chief Executive Officer at a public medical device company. This transition signifies a significant change in the Company's leadership as it prepares for future strategic initiatives and may affect its commercial strategy. The announcement highlights the Company's commitment to maintaining robust leadership during this transition period.
- : SEC 8-K (1.01): On July 6, 2026, Tarsus Pharmaceuticals, Inc. entered into a Merger Agreement with iRenix Medical, Inc. and its wholly-owned subsidiary Dolores Merger Sub, Inc. Under the terms of the Agreement, Merger Sub merged with iRenix, which will become a wholly-owned subsidiary of Tarsus. The total upfront consideration for this acquisition includes $37,500,000 in cash and 607,093 shares of Tarsus common stock, with potential additional milestone payments of up to $490,000,000 contingent on regulatory approvals and sales. The Merger Agreement includes customary representations and warranties and is a significant strategic move for the Company, enhancing its portfolio in the medical sector.
- : SEC 8-K (5.02): On February 18, 2026, Tarsus Pharmaceuticals, Inc. expanded its Board of Directors from seven to eight members by appointing David E.I. Pyott as a Class III director, effective immediately. Mr. Pyott's term will last until the Company's 2026 annual meeting of stockholders. Additionally, he has been designated as the Chairperson of the Commercial Committee and a member of both the Nominating Committee and the Compensation Committee. As part of his compensation, Mr. Pyott will receive a package valued at $540,000, split between stock options and restricted stock units. An indemnification agreement has also been established with him, mirroring those of other directors, ensuring his protection as a newly appointed member of the Board.
Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.
Tarsus Pharmaceuticals funding history
| Date | Round | Amount |
|---|---|---|
| Aug 2026 | Post-IPO Equity | $125.0M |
Leadership
- Cindy, Sr. Director, Talent
- Neera Clase, Chief Commercial Officer
- Aziz, Chief Commercial Officer
- Elizabeth Yeu, Chief Medical Officer
Verified email and direct lines for Tarsus Pharmaceuticals’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.
Employee benefit plans
Tarsus Pharmaceuticals files 2 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Tarsus Pharmaceuticals in the news
- Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership Position - GlobeNewswire (Aug 06, 2026)
- Tarsus to Participate in Upcoming Investor Conferences - GlobeNewswire (Nov 05, 2026)
- Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care - GlobeNewswire (Sep 04, 2026)
- Tarsus Pharmaceuticals Announces Oversubscribed $125.0 Million Private Placement Equity Financing - GlobeNewswire (Aug 06, 2026)
- Tarsus Pharmaceuticals Appoints Neera Clase as Chief Commercial Officer - GlobeNewswire (Oct 28, 2026)
- Tarsus to Participate in Upcoming Investor Conferences - GlobeNewswire (Sep 01, 2026)
- Tarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of Growth - GlobeNewswire (Jul 13, 2026)
- Tarsus to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026 - GlobeNewswire (Oct 29, 2026)
Companies similar to Tarsus Pharmaceuticals
- MacroGenics · Biopharma, Biotechnology, Health Care, Manufacturing, Pharmaceutical, Therapeutics
- TerSera · Biopharma, Biotechnology, Health Care, Manufacturing, Pharmaceutical, Therapeutics
- CASI Pharmaceuticals · Biopharma, Biotechnology, Health Care, Manufacturing, Pharmaceutical, Therapeutics
- Jubilant Therapeutics · Biopharma, Biotechnology, Health Care, Manufacturing, Pharmaceutical, Therapeutics
- AnHeart Therapeutics · Biopharma, Biotechnology, Health Care, Manufacturing, Pharmaceutical, Therapeutics
About Tarsus Pharmaceuticals: questions and answers
What does Tarsus Pharmaceuticals do?
Tarsus Pharmaceuticals, Inc. is a company specializing in biological products. They have shown substantial growth and have strategic initiatives in place, including the recent appointment of Dr. Elizabeth Yeu as the new Chief Medical Officer.
Where is Tarsus Pharmaceuticals headquartered?
Tarsus Pharmaceuticals is headquartered in Irvine, California, United States.
How many employees does Tarsus Pharmaceuticals have?
Tarsus Pharmaceuticals has about 370 employees.
Has Tarsus Pharmaceuticals raised funding?
Yes. Fundz has recorded 1 funding event for Tarsus Pharmaceuticals. The most recent, Post-IPO Equity of $125.0M, was in Aug 2026.
What is the latest news on Tarsus Pharmaceuticals?
On Aug 6, 2026, Tarsus Pharmaceuticals to acquire Alkeus Pharmaceuticals
Is Tarsus Pharmaceuticals a public company?
Yes. Tarsus Pharmaceuticals is publicly traded under the ticker TARS.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy